The gabapentin market was estimated to be worth USD 2.5 billion globally in 2022, and over the course of the projected period, a CAGR of 2.6% is anticipated. The market is expanding due to a number of factors, including a rise in the prevalence of seizures, an aging population, more government initiatives, easier purchasing, rising disposable income, and increased funding for R&D.
The market is expanding due to an increase in the number of neurological disorders being treated, the growing use of gabapentin in pain management, and the increased knowledge of medical professionals regarding the drug's potential benefits in treating neuropathic disorders. The drug's clearance for a number of ailments encourages market growth even further.

Request For Free Sample Pages @ https://www.xresearch.biz/request-sample-pages/gabapentin-market

Impact of Covid-19
There has been a mixed effect of COVID-19 on the gabapentin market. Growth may be fueled, on the one hand, by the rising need for drugs that treat neurological conditions. The pandemic-related disruptions to the healthcare system and pharmaceutical supply chain have severely impeded market expansion. Growing public awareness and education campaigns are propelling the market's expansion, and growing knowledge of neurological illnesses has greatly aided in its success.
Growth Drivers
The market is growing at a substantial rate due to factors including growing health consciousness among the populace, rising disposable income, growing knowledge of neurological illnesses, and developing applications in pain treatment. Growth in the area is being propelled by gabapentin's adaptability in providing effective and efficient treatment for a range of medical disorders.
The market is expanding due to rising demand for gabapentin as a treatment for migraines and anxiety disorders. Doctors and other medical professionals are confidently prescribing this medication to treat a variety of illnesses. The market for gabapentin is expanding dramatically, driven mostly by the rising prevalence of cardiovascular illnesses and seizures. Governments from all around the world are heavily funding research and development, which has greatly expanded this sector. The market is expanding because to the rising prevalence of seizures and neurological illnesses.
Segmentation
Product Type
· Capsule
· Tablet
Route of Administration
· Oral
· Parenteral
· Intravenous
Application
· Epilepsy
· Neuropathic pain
· Restless Legs
Mode of Purchase
· Prescription
· Retail
· Over the counter
Distribution Channel
· Hospitals
· Retail Pharmacies
· Online
Regional Outlook
· Asia Pacific
· North America
· Europe
· Latin America
· Middle East and Asia Pacific

Key Players
· Amagen Inc
· Bristol Myers Squibb Co.
· Erytech Pharma
· Novartis AG
· Pfizer Inc
· Rare Disease Therapeutics Inc
· Baxter
· Aurobindo Pharma limited
· Zydus Cadila Healthcare ltd
· Hikma Pharmaceuticals Plc
· Dr. Reddy’s laboratories ltd
· Mylan N.V.
· Torrent pharmaceuticals ltd
· Eisai Company Limited
· Kiddis Pharma
· OBI Pharma
· Celgene Corporation
· Spectrum Pharmaceuticals
· Other Players

For More Information about this Report @ https://www.xresearch.biz/shop/gabapentin-market

About Us: -
xResearch is a market research and consulting organization that uses unique data, expert analysis, and new technologies to create trusted intelligence on industries. Our research is focused on delivering an informed and impartial view on essential market data of industry, and it is primarily driven by an in-depth study covering the following parameters: Market Sizing and Forecasting, Market Segmentation, Competitive Analysis, Strategic Assessment and Business Modelling.

Contact:
Company Name: xResearch
Contact Person: James Lin
Email: [email protected]
Phone: +1 718-618-4545